Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

iNtRON Biotechnology Inc Announces KFDA Approval


Thursday, 24 Jan 2013 03:28am EST 

iNtRON Biotechnology Inc announced that it has received an approval from Korea Food & Drug Administration (KFDA) to initiate a clinical testing for N-Rephasin SAL200. 

Company Quote

14150.0
200.0 +1.43%
2:00am EDT